BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 3916661)

  • 1. Cells responsible for tumor surveillance in man: effects of radiotherapy, chemotherapy, and biologic response modifiers.
    Reizenstein P; Ogier C; Blomgren H; Petrini B; Wasserman J
    Adv Immun Cancer Ther; 1985; 1():1-28. PubMed ID: 3916661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophages, NK-cells, NK-like cells, and tumor surveillance in man.
    Reizenstein P
    Biomed Pharmacother; 1985; 39(1):1-3. PubMed ID: 3875368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G; Malorni W; Donelli G
    Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of natural killer cells and other effector cells in immune surveillance against cancer.
    Herberman RB
    J Invest Dermatol; 1984 Jul; 83(1 Suppl):137s-140s. PubMed ID: 6376648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The innate immune response to tumors and its role in the induction of T-cell immunity.
    Diefenbach A; Raulet DH
    Immunol Rev; 2002 Oct; 188():9-21. PubMed ID: 12445277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression following 7,12-dimethylbenz[a]anthracene exposure in B6C3F1 mice--II. Altered cell-mediated immunity and tumor resistance.
    Dean JH; Ward EC; Murray MJ; Lauer LD; House RV; Stillman W; Hamilton TA; Adams DO
    Int J Immunopharmacol; 1986; 8(2):189-98. PubMed ID: 3086244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological response modifiers: regulators of the cellular immune system and adjuvants in antitumor therapy.
    Chirigos MA; Schlick E; Saito T; Gruys E
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):27-33. PubMed ID: 3486334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells.
    Itoh K; Platsoucas CD; Balch CM
    Cell Immunol; 1987 Sep; 108(2):495-500. PubMed ID: 3113744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of murine susceptibility to tumor, parasite and bacterial challenge with altered cell-mediated immunity following systemic exposure to the tumor promoter phorbol myristate acetate.
    Murray MJ; Lauer LD; Luster MI; Luebke RW; Adams DO; Dean JH
    Int J Immunopharmacol; 1985; 7(4):491-500. PubMed ID: 3876295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
    Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
    Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.
    Komada Y; Zhang SL; Zhou YW; Hanada M; Shibata T; Azuma E; Sakurai M
    Cancer Immunol Immunother; 1992; 35(4):271-6. PubMed ID: 1511462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
    Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
    Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceleration of age-associated immune decline and mortality by early repeated administration of bestatin to C57BL/6 mice.
    Bruley-Rosset M; Payelle B; Rappaport H
    J Biol Response Mod; 1986 Apr; 5(2):176-90. PubMed ID: 3488372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An introduction to tumour immunology.
    Keith J
    Mater Med Pol; 1984; 16(1):54-64. PubMed ID: 6394909
    [No Abstract]   [Full Text] [Related]  

  • 19. [Natural cytotoxic cells (NK) and their role in the immunological control of neoplasms].
    Rupniewska ZM; Adamczyk MB
    Postepy Hig Med Dosw; 1981; 35(1):37-52. PubMed ID: 6174960
    [No Abstract]   [Full Text] [Related]  

  • 20. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance.
    Chang CC; Ferrone S
    Semin Cancer Biol; 2006 Oct; 16(5):383-92. PubMed ID: 16931041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.